| 000 | 01694 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250517042316.0 | ||
| 264 | 0 | _c20160713 | |
| 008 | 201607s 0 0 eng d | ||
| 022 | _a2045-7634 | ||
| 024 | 7 |
_a10.1002/cam4.491 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGolan, Talia | |
| 245 | 0 | 0 |
_aPegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients. _h[electronic resource] |
| 260 |
_bCancer medicine _cOct 2015 |
||
| 300 |
_a1472-83 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAnemia _xchemically induced |
| 650 | 0 | 4 |
_aAntibiotics, Antineoplastic _xadministration & dosage |
| 650 | 0 | 4 |
_aFatigue _xchemically induced |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aLiposomes |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMaximum Tolerated Dose |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMitomycin _xadministration & dosage |
| 650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
| 650 | 0 | 4 | _aPolyethylene Glycols |
| 650 | 0 | 4 |
_aProdrugs _xadministration & dosage |
| 650 | 0 | 4 | _aResponse Evaluation Criteria in Solid Tumors |
| 650 | 0 | 4 |
_aThrombocytopenia _xchemically induced |
| 700 | 1 | _aGrenader, Tal | |
| 700 | 1 | _aOhana, Patricia | |
| 700 | 1 | _aAmitay, Yasmine | |
| 700 | 1 | _aShmeeda, Hilary | |
| 700 | 1 | _aLa-Beck, Ninh M | |
| 700 | 1 | _aTahover, Esther | |
| 700 | 1 | _aBerger, Raanan | |
| 700 | 1 | _aGabizon, Alberto A | |
| 773 | 0 |
_tCancer medicine _gvol. 4 _gno. 10 _gp. 1472-83 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/cam4.491 _zAvailable from publisher's website |
| 999 |
_c25071903 _d25071903 |
||